www.fdanews.com/articles/180857-nice-endorses-intercepts-ocaliva-as-treatment-for-chronic-liver-disease
NICE Endorses Intercept’s Ocaliva as Treatment for Chronic Liver Disease
March 13, 2017
The National Institute for Health and Care Excellence approves of Intercept’s Ocaliva for routine NHS commissioning as a treatment for people with the chronic liver disease primary biliary cholangitis.
Ocaliva is an option for patients that do not fully respond to or are intolerant to the current treatment.
The treatment was approved by EU regulators in December 2016.